Your Article Summary
See Latest ArticlesBorrello IM et al. - A decrease in WT1 transcripts in blood was noted in 69% of patients following the first immunotherapy dose and was also associated with longer 3-year RFS (61% vs. 0%). In conclusion, immunotherapy in combination with primed lymphocytes and ASCT shows encouraging signals of potential activity in AML.
Related Articles
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia
Blood, 12/01/09
Relevance Score: 82%
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, 12/02/09
Relevance Score: 81%
Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia
Cancer Science, 11/25/09
Relevance Score: 81%
Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11 acute myeloid leukemias
Blood, 11/25/09
Relevance Score: 81%
MicroRNA 29b functions in acute myeloid leukemia
Blood, 11/09/09
Relevance Score: 81%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Dysregulation of Platelet-Derived Growth Factor beta-Receptor Expression by deltaNp73 in Neuroblastoma
Molecular Cancer Research, 12/04/09
Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression
Virchows Archiv, 12/04/09
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent diagnoses of Hodgkin lymphoma and biclonal myeloma in the bone marrow
Annals of Diagnostic Pathology, 12/04/09
Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience
Acta Haematologica, 12/04/09
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
Journal of Clinical Oncology, 12/04/09